<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00112125</url>
  </required_header>
  <id_info>
    <org_study_id>#IDPT 2003-07-C</org_study_id>
    <secondary_id>FIX-HF-5</secondary_id>
    <nct_id>NCT00112125</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Effectiveness of the OPTIMIZER System in Subjects With Heart Failure: FIX-HF-5</brief_title>
  <official_title>Evaluation of the Safety and Efficacy of the OPTIMIZER System With Active Fixation Leads in Subjects With Heart Failure Resulting From Systolic Dysfunction: FIX-HF-5</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Impulse Dynamics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Impulse Dynamics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment with the OPTIMIZER System is safe&#xD;
      and effective in patients with moderate to severe heart failure symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IMPULSE Dynamics' FIX HF 5 US Study is a prospective, multi-center, study to evaluate the&#xD;
      safety and efficacy of cardiac contractility modulation (CCM) signals delivered by the&#xD;
      implantable OPTIMIZER™ System in patients with NYHA class III/IV heart failure. The study&#xD;
      will involve the recruitment of approximately 420 subjects at a total of up to 50 sites&#xD;
      nationwide.&#xD;
&#xD;
      Those subjects who fulfill all inclusion and exclusion criteria based upon baseline test&#xD;
      results will be randomized to receive the OPTIMIZER™ System or to a control group. All&#xD;
      subjects randomized will be followed for 1 year and shall receive the same study related&#xD;
      assessments throughout the course of the study. In addition, all subjects will continue to&#xD;
      receive optimal medical therapy for the treatment of their heart failure.&#xD;
&#xD;
      The primary efficacy assessment consists of a change in exercise tolerance measured by&#xD;
      cardiopulmonary exercise testing at baseline and 6 months. Safety variables, such as the rate&#xD;
      and cause of hospitalizations or death, shall be collected in both groups and shall be&#xD;
      compared at 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2005</start_date>
  <completion_date type="Actual">March 19, 2019</completion_date>
  <primary_completion_date type="Actual">March 19, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Endpoint: Ventilatory Anerobic Threshold (VAT)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of participants with improvement in exercise tolerance at 24 weeks compared to baseline, as quantified by VO2 at ventilatory anerobic threshold (VAT) measured on cardiopulmonary exercise stress testing (CPX), and evaluated by a blinded core lab.&#xD;
Note: An individual subject is considered a responder if VAT increases by ≥20% at 24 weeks compared to their respective baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Endpoint: Composite All-cause Mortality and All-cause Hospitalizations</measure>
    <time_frame>50-weeks</time_frame>
    <description>The proportion of patients experiencing a composite event of all-cause mortality and all-cause hospitalizations evaluated at 50-weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak VO2</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of participants with improvement in peak VO2 measured on cardiopulmonary exercise stress testing (CPX), and evaluated by a blinded core lab.&#xD;
Note: An individual subject is considered a responder if peak VO2 increases by ≥20% at 24 weeks compared to their respective baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Functional Classification</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of participants with improvement in heart failure symptoms as quantified by a blinded clinician using the New York Heart Association (NYHA) functional classification at 24 weeks compared to baseline. The NYHA Class ranges from I - IV, with a lower class indicating a better status.&#xD;
Note: An individual subject is considered a responder if the NYHA class decreases by ≥ 1 at 24 weeks compared to their respective baseline class.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minnesota Living With Heart Failure (MLWHF) Questionnaire</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of subjects will improvement in quality of life at 24 weeks compared to baseline, as assessed by the Minnesota Living with Heart Failure (MLWHF) Questionnaire. The MLWHFQ score could range from 0 to 105, with higher scores indicating more significant impairment in health-related quality of life.&#xD;
Note: An individual subject is considered a responder if the MLWHFQ score decreases by ≥10 points at 24 weeks compared to their respective baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six Minute Hall Walk (6MW) Test</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of subjects with improvement in exercise tolerance at 24 weeks compared to baseline, as assessed by the the six minute hall walk (6MW) test.&#xD;
Note: An individual subject is considered a responder with &gt;40-meter increase in distance walked at 24 weeks compared to their respective baseline distance.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">428</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>Optimizer System + Optimal medical treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimizer System implanted and cardiac contractility modulation therapy activated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal medical treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treatment with optimal medical therapy only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OPTIMIZER System</intervention_name>
    <arm_group_label>Optimizer System + Optimal medical treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who are 18 years of age or older&#xD;
&#xD;
          -  Subjects who are either male or female&#xD;
&#xD;
          -  Subjects who have a baseline ejection fraction of 35% or less by echocardiography.&#xD;
&#xD;
          -  Subjects who have been treated for heart failure for at least 90 days (including&#xD;
             treatment with a β-blocker for at least 90 days unless the patient is intolerant) and&#xD;
             are in New York Heart Association functional Class III or IV at the time of&#xD;
             enrollment.&#xD;
&#xD;
          -  Subjects receiving appropriate, stable medical therapy during the 30 days prior to&#xD;
             enrollment for treatment of heart failure, consisting of the appropriate doses of&#xD;
             diuretics, ACE-inhibitor or angiotensin II receptor blocker and β-blocker. Stable is&#xD;
             defined as no more than a 100% increase or 50% decrease in dose.&#xD;
&#xD;
          -  Subjects who, in the opinion of the Principle Investigator (based on the current&#xD;
             guidelines for clinical practice), have a clinical indication for an implanted cardiac&#xD;
             defibrillator (ICD) and/or pacemaker, must have an existing device or agree to undergo&#xD;
             implantation of such a device unless the patient refuses to undergo the implantation&#xD;
             of such device for personal reasons.&#xD;
&#xD;
          -  Subjects who are willing and able to return for all follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects whose baseline VO2,max is &lt;9 ml 02/min/kg.&#xD;
&#xD;
          -  Subjects who have a potentially correctible cause of heart failure, such as valvular&#xD;
             heart disease or congenital heart disease.&#xD;
&#xD;
          -  Subjects who have clinically significant angina pectoris, consisting of angina during&#xD;
             daily life (i.e., Canadian Cardiovascular Society Angina score of II or more), an&#xD;
             episode of unstable angina within 30 days of enrollment, or angina and/or&#xD;
             electrocardiography (ECG) changes during exercise testing performed during baseline&#xD;
             evaluation.&#xD;
&#xD;
          -  Subjects who have been hospitalized for heart failure which required the use of&#xD;
             inotropic support within 30 days of enrollment.&#xD;
&#xD;
          -  Subjects who have a clinically significant amount of ambient ectopy, defined as more&#xD;
             than 8,900 premature ventricular complexes (PVCs) per 24 hours on baseline Holter&#xD;
             monitoring.&#xD;
&#xD;
          -  Subjects who have chronic atrial fibrillation or chronic atrial flutter or those&#xD;
             cardioverted within 30 days of enrollment.&#xD;
&#xD;
          -  Subjects whose exercise tolerance is limited by a condition other than heart failure&#xD;
             (e.g., angina, chronic obstructive pulmonary disease [COPD], peripheral vascular&#xD;
             disease, orthopedic or rheumatologic conditions) or who are unable to participate in a&#xD;
             6-minute walk or a cardiopulmonary stress test.&#xD;
&#xD;
          -  Subjects who are scheduled for a coronary artery bypass graft (CABG) or a percutaneous&#xD;
             transluminal coronary angioplasty (PTCA) procedure, or who have undergone a CABG&#xD;
             procedure within 90 days or a PTCA procedure within 30 days of enrollment.&#xD;
&#xD;
          -  Subjects who have a biventricular pacing system or who have an accepted indication for&#xD;
             such a device.&#xD;
&#xD;
          -  Subjects who have had a myocardial infarction within 90 days of enrollment.&#xD;
&#xD;
          -  Subjects who have mechanical tricuspid or aortic valves.&#xD;
&#xD;
          -  Subjects who have a prior heart transplant.&#xD;
&#xD;
          -  Subjects who are participating in another experimental protocol.&#xD;
&#xD;
          -  Subjects who are unable to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Burkhoff, M.D, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Impulse Dynamics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Impulse Dynamics</name>
      <address>
        <city>Orangeburg</city>
        <state>New York</state>
        <zip>10962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Burkhoff D, Shemer I, Felzen B, Shimizu J, Mika Y, Dickstein M, Prutchi D, Darvish N, Ben-Haim SA. Electric currents applied during the refractory period can modulate cardiac contractility in vitro and in vivo. Heart Fail Rev. 2001 Jan;6(1):27-34. Review.</citation>
    <PMID>11248765</PMID>
  </reference>
  <reference>
    <citation>Ellison K. Nonexcitatory stimulation: 2002: a pace odyssey. J Cardiovasc Electrophysiol. 2002 Jul;13(7):696-7.</citation>
    <PMID>12139295</PMID>
  </reference>
  <reference>
    <citation>Marrouche NF, Pavia SV, Zhuang S, Kim YJ, Tabata T, Wallick D, Saad E, Abdul-Karim A, Schweikert R, Saliba W, Tchou P, Natale A. Nonexcitatory stimulus delivery improves left ventricular function in hearts with left bundle branch block. J Cardiovasc Electrophysiol. 2002 Jul;13(7):691-5.</citation>
    <PMID>12139294</PMID>
  </reference>
  <reference>
    <citation>Mohri S, He KL, Dickstein M, Mika Y, Shimizu J, Shemer I, Yi GH, Wang J, Ben-Haim S, Burkhoff D. Cardiac contractility modulation by electric currents applied during the refractory period. Am J Physiol Heart Circ Physiol. 2002 May;282(5):H1642-7.</citation>
    <PMID>11959626</PMID>
  </reference>
  <reference>
    <citation>Morita H, Suzuki G, Haddad W, Mika Y, Tanhehco EJ, Sharov VG, Goldstein S, Ben-Haim S, Sabbah HN. Cardiac contractility modulation with nonexcitatory electric signals improves left ventricular function in dogs with chronic heart failure. J Card Fail. 2003 Feb;9(1):69-75.</citation>
    <PMID>12612875</PMID>
  </reference>
  <reference>
    <citation>Mohri S, Shimizu J, Mika Y, Shemer I, Wang J, Ben-Haim S, Burkhoff D. Electric currents applied during refractory period enhance contractility and systolic calcium in the ferret heart. Am J Physiol Heart Circ Physiol. 2003 Apr;284(4):H1119-23. Epub 2002 Nov 21.</citation>
    <PMID>12446280</PMID>
  </reference>
  <reference>
    <citation>Sabbah HN, Haddad W, Mika Y, Nass O, Aviv R, Sharov VG, Maltsev V, Felzen B, Undrovinas AI, Goldstein S, Darvish N, Ben-Haim SA. Cardiac contractility modulation with the impulse dynamics signal: studies in dogs with chronic heart failure. Heart Fail Rev. 2001 Jan;6(1):45-53. Review.</citation>
    <PMID>11248767</PMID>
  </reference>
  <reference>
    <citation>Pappone C, Rosanio S, Burkhoff D, Mika Y, Vicedomini G, Augello G, Shemer I, Prutchi D, Haddad W, Aviv R, Snir Y, Kronzon I, Alfieri O, Ben-Haim SA. Cardiac contractility modulation by electric currents applied during the refractory period in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2002 Dec 15;90(12):1307-13.</citation>
    <PMID>12480039</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 27, 2005</study_first_submitted>
  <study_first_submitted_qc>May 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2005</study_first_posted>
  <results_first_submitted>April 20, 2020</results_first_submitted>
  <results_first_submitted_qc>July 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2020</results_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiac contractility modulation</keyword>
  <keyword>heart failure</keyword>
  <keyword>cardiopulmonary exercise test</keyword>
  <keyword>chronic heart disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 7, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT00112125/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Group (OMT)</title>
          <description>Optimal medical treatment (OMT). Subjects receiving appropriate, stable medical therapy during the 30 days prior to enrollment for treatment of heart failure, consisting of the appropriate doses of diuretics, ACE-inhibitor or angiotensin II receptor blocker and B-blocker.</description>
        </group>
        <group group_id="P2">
          <title>Treatment (CCM + OMT)</title>
          <description>Treatment group: Subjects receiving OMT and cardiac contractility modulation therapy with the Optimizer System.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="213"/>
                <participants group_id="P2" count="215"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="193"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group (OMT)</title>
          <description>Optimal medical treatment (OMT). Subjects receiving appropriate, stable medical therapy during the 30 days prior to enrollment for treatment of heart failure, consisting of the appropriate doses of diuretics, ACE-inhibitor or angiotensin II receptor blocker and B-blocker.</description>
        </group>
        <group group_id="B2">
          <title>Treatment (OMT + CCM)</title>
          <description>Treatment group: Subjects receiving OMT and cardiac contractility modulation therapy with the Optimizer System.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="213"/>
            <count group_id="B2" value="215"/>
            <count group_id="B3" value="428"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="12.2"/>
                    <measurement group_id="B2" value="58.1" spread="12.8"/>
                    <measurement group_id="B3" value="58.35" spread="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="296"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peak VO2</title>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.71" spread="2.92"/>
                    <measurement group_id="B2" value="14.74" spread="3.06"/>
                    <measurement group_id="B3" value="14.725" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>6 Minute Hall Walk Distance</title>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="324" spread="92.4"/>
                    <measurement group_id="B2" value="326.4" spread="82.1"/>
                    <measurement group_id="B3" value="325.2" spread="7.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA Class III</title>
          <description>Class I: Ordinary physical activity does not cause undue dyspnea or fatigue.&#xD;
Class II: Comfortable at rest. Ordinary physical activity results in dyspnea or fatigue.&#xD;
Class III: Comfortable at rest. Less than ordinary physical activity results in dyspnea or fatigue.&#xD;
Class IV: Symptoms of heart failure may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA Class IV</title>
          <description>Class I: Ordinary physical activity does not cause undue dyspnea or fatigue.&#xD;
Class II: Comfortable at rest. Ordinary physical activity results in dyspnea or fatigue.&#xD;
Class III: Comfortable at rest. Less than ordinary physical activity results in dyspnea or fatigue.&#xD;
Class IV: Symptoms of heart failure may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MLWHFQ score</title>
          <description>Minnessotta Living with Heart Failure Questionnaire score. There are 21 questions completed by the participant, with each response on a scale of 0-5. The total score ranges from 0 to 105, with higher scores indicating more significant impairment in health-related quality of life.</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.4" spread="22.6"/>
                    <measurement group_id="B2" value="60.5" spread="23"/>
                    <measurement group_id="B3" value="58.95" spread="0.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy Endpoint: Ventilatory Anerobic Threshold (VAT)</title>
        <description>Number of participants with improvement in exercise tolerance at 24 weeks compared to baseline, as quantified by VO2 at ventilatory anerobic threshold (VAT) measured on cardiopulmonary exercise stress testing (CPX), and evaluated by a blinded core lab.&#xD;
Note: An individual subject is considered a responder if VAT increases by ≥20% at 24 weeks compared to their respective baseline value.</description>
        <time_frame>24 weeks</time_frame>
        <population>Intention to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group (OMT)</title>
            <description>Optimal medical treatment (OMT). Subjects receiving appropriate, stable medical therapy during the 30 days prior to enrollment for treatment of heart failure, consisting of the appropriate doses of diuretics, ACE-inhibitor or angiotensin II receptor blocker and B-blocker.</description>
          </group>
          <group group_id="O2">
            <title>Treatment (CCM + OMT)</title>
            <description>Treatment group: Subjects receiving OMT and cardiac contractility modulation therapy with the Optimizer System.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Endpoint: Ventilatory Anerobic Threshold (VAT)</title>
          <description>Number of participants with improvement in exercise tolerance at 24 weeks compared to baseline, as quantified by VO2 at ventilatory anerobic threshold (VAT) measured on cardiopulmonary exercise stress testing (CPX), and evaluated by a blinded core lab.&#xD;
Note: An individual subject is considered a responder if VAT increases by ≥20% at 24 weeks compared to their respective baseline value.</description>
          <population>Intention to treat (ITT) population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The primary safety analysis was a test of the non-inferiority of CCM therapy compared to OMT with respect to the proportion of subjects experiencing death or hospitalization within 50 weeks using the Blackwelder non-inferiority test12 with a prespecified non-inferiority margin of 0.125.</non_inferiority_desc>
            <p_value>0.31</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Endpoint: Composite All-cause Mortality and All-cause Hospitalizations</title>
        <description>The proportion of patients experiencing a composite event of all-cause mortality and all-cause hospitalizations evaluated at 50-weeks</description>
        <time_frame>50-weeks</time_frame>
        <population>Intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group (OMT)</title>
            <description>Optimal medical treatment (OMT). Subjects receiving appropriate, stable medical therapy during the 30 days prior to enrollment for treatment of heart failure, consisting of the appropriate doses of diuretics, ACE-inhibitor or angiotensin II receptor blocker and B-blocker.</description>
          </group>
          <group group_id="O2">
            <title>Treatment (CCM + OMT)</title>
            <description>Treatment group: Subjects receiving OMT and cardiac contractility modulation therapy with the Optimizer System.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: Composite All-cause Mortality and All-cause Hospitalizations</title>
          <description>The proportion of patients experiencing a composite event of all-cause mortality and all-cause hospitalizations evaluated at 50-weeks</description>
          <population>Intention-to-treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The noninferiority margin was selected to be 12.5% and α was set at .05, which resulted in a sample size of 198 subjects per group. A percentage of subjects (∼7%) were expected to be lost to followup, so that a total sample size of 428 subjects (214 per group) was selected.</non_inferiority_desc>
            <p_value>0.125</p_value>
            <method>Blackwelder</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak VO2</title>
        <description>Number of participants with improvement in peak VO2 measured on cardiopulmonary exercise stress testing (CPX), and evaluated by a blinded core lab.&#xD;
Note: An individual subject is considered a responder if peak VO2 increases by ≥20% at 24 weeks compared to their respective baseline value.</description>
        <time_frame>24 weeks</time_frame>
        <population>Completed cases</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group (OMT)</title>
            <description>Optimal medical treatment (OMT). Subjects receiving appropriate, stable medical therapy during the 30 days prior to enrollment for treatment of heart failure, consisting of the appropriate doses of diuretics, ACE-inhibitor or angiotensin II receptor blocker and B-blocker.</description>
          </group>
          <group group_id="O2">
            <title>Treatment (CCM + OMT)</title>
            <description>Treatment group: Subjects receiving OMT and cardiac contractility modulation therapy with the Optimizer System.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak VO2</title>
          <description>Number of participants with improvement in peak VO2 measured on cardiopulmonary exercise stress testing (CPX), and evaluated by a blinded core lab.&#xD;
Note: An individual subject is considered a responder if peak VO2 increases by ≥20% at 24 weeks compared to their respective baseline value.</description>
          <population>Completed cases</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New York Heart Association (NYHA) Functional Classification</title>
        <description>Number of participants with improvement in heart failure symptoms as quantified by a blinded clinician using the New York Heart Association (NYHA) functional classification at 24 weeks compared to baseline. The NYHA Class ranges from I - IV, with a lower class indicating a better status.&#xD;
Note: An individual subject is considered a responder if the NYHA class decreases by ≥ 1 at 24 weeks compared to their respective baseline class.</description>
        <time_frame>24 weeks</time_frame>
        <population>Completed cases</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group (OMT)</title>
            <description>Optimal medical treatment (OMT). Subjects receiving appropriate, stable medical therapy during the 30 days prior to enrollment for treatment of heart failure, consisting of the appropriate doses of diuretics, ACE-inhibitor or angiotensin II receptor blocker and B-blocker.</description>
          </group>
          <group group_id="O2">
            <title>Treatment (CCM + OMT)</title>
            <description>Treatment group: Subjects receiving OMT and cardiac contractility modulation therapy with the Optimizer System.</description>
          </group>
        </group_list>
        <measure>
          <title>New York Heart Association (NYHA) Functional Classification</title>
          <description>Number of participants with improvement in heart failure symptoms as quantified by a blinded clinician using the New York Heart Association (NYHA) functional classification at 24 weeks compared to baseline. The NYHA Class ranges from I - IV, with a lower class indicating a better status.&#xD;
Note: An individual subject is considered a responder if the NYHA class decreases by ≥ 1 at 24 weeks compared to their respective baseline class.</description>
          <population>Completed cases</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minnesota Living With Heart Failure (MLWHF) Questionnaire</title>
        <description>Number of subjects will improvement in quality of life at 24 weeks compared to baseline, as assessed by the Minnesota Living with Heart Failure (MLWHF) Questionnaire. The MLWHFQ score could range from 0 to 105, with higher scores indicating more significant impairment in health-related quality of life.&#xD;
Note: An individual subject is considered a responder if the MLWHFQ score decreases by ≥10 points at 24 weeks compared to their respective baseline score.</description>
        <time_frame>24 weeks</time_frame>
        <population>Completed cases</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group (OMT)</title>
            <description>Optimal medical treatment (OMT). Subjects receiving appropriate, stable medical therapy during the 30 days prior to enrollment for treatment of heart failure, consisting of the appropriate doses of diuretics, ACE-inhibitor or angiotensin II receptor blocker and B-blocker.</description>
          </group>
          <group group_id="O2">
            <title>Treatment (CCM + OMT)</title>
            <description>Treatment group: Subjects receiving OMT and cardiac contractility modulation therapy with the Optimizer System.</description>
          </group>
        </group_list>
        <measure>
          <title>Minnesota Living With Heart Failure (MLWHF) Questionnaire</title>
          <description>Number of subjects will improvement in quality of life at 24 weeks compared to baseline, as assessed by the Minnesota Living with Heart Failure (MLWHF) Questionnaire. The MLWHFQ score could range from 0 to 105, with higher scores indicating more significant impairment in health-related quality of life.&#xD;
Note: An individual subject is considered a responder if the MLWHFQ score decreases by ≥10 points at 24 weeks compared to their respective baseline score.</description>
          <population>Completed cases</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Six Minute Hall Walk (6MW) Test</title>
        <description>Number of subjects with improvement in exercise tolerance at 24 weeks compared to baseline, as assessed by the the six minute hall walk (6MW) test.&#xD;
Note: An individual subject is considered a responder with &gt;40-meter increase in distance walked at 24 weeks compared to their respective baseline distance.</description>
        <time_frame>24 weeks</time_frame>
        <population>Completed cases</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group (OMT)</title>
            <description>Optimal medical treatment (OMT). Subjects receiving appropriate, stable medical therapy during the 30 days prior to enrollment for treatment of heart failure, consisting of the appropriate doses of diuretics, ACE-inhibitor or angiotensin II receptor blocker and B-blocker.</description>
          </group>
          <group group_id="O2">
            <title>Treatment (CCM + OMT)</title>
            <description>Treatment group: Subjects receiving OMT and cardiac contractility modulation therapy with the Optimizer System.</description>
          </group>
        </group_list>
        <measure>
          <title>Six Minute Hall Walk (6MW) Test</title>
          <description>Number of subjects with improvement in exercise tolerance at 24 weeks compared to baseline, as assessed by the the six minute hall walk (6MW) test.&#xD;
Note: An individual subject is considered a responder with &gt;40-meter increase in distance walked at 24 weeks compared to their respective baseline distance.</description>
          <population>Completed cases</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>50-weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control Group (OMT)</title>
          <description>Optimal medical treatment (OMT). Subjects receiving appropriate, stable medical therapy during the 30 days prior to enrollment for treatment of heart failure, consisting of the appropriate doses of diuretics, ACE-inhibitor or angiotensin II receptor blocker and B-blocker.</description>
        </group>
        <group group_id="E2">
          <title>Treatment (CCM + OMT)</title>
          <description>Treatment group: Subjects receiving OMT and cardiac contractility modulation therapy with the Optimizer System.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="212"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>OPTIMIZER pocket bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>General Cardiopulmonary Event</sub_title>
                <counts group_id="E1" events="58" subjects_affected="46" subjects_at_risk="212"/>
                <counts group_id="E2" events="60" subjects_affected="42" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="25" subjects_at_risk="212"/>
                <counts group_id="E2" events="40" subjects_affected="29" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>ICD or Pacemaker System Malfunction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="212"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Worsening Heart Failure</sub_title>
                <counts group_id="E1" events="85" subjects_affected="50" subjects_at_risk="212"/>
                <counts group_id="E2" events="72" subjects_affected="50" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Medical</sub_title>
                <counts group_id="E1" events="81" subjects_affected="54" subjects_at_risk="212"/>
                <counts group_id="E2" events="98" subjects_affected="63" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Localized Infection</sub_title>
                <counts group_id="E1" events="36" subjects_affected="29" subjects_at_risk="212"/>
                <counts group_id="E2" events="33" subjects_affected="27" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>OPTIMIZER pocket infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic Dysfunction</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="212"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>OPTIMIZER lead fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>OPTIMIZER RV lead dislodgement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>IPG problem/change</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>OPTIMIZER RA lead dislodgement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>OPTIMIZER pocket dehiscence/erosion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>OPTIMIZER pocket stimulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Lead perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Sensation due to CCM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Extracardiac stimulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="212"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>General Cardiopulmonary Event</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="212"/>
                <counts group_id="E2" events="55" subjects_affected="41" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Arrhythmias</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="212"/>
                <counts group_id="E2" events="29" subjects_affected="26" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Worsening Heart Failure</sub_title>
                <counts group_id="E1" events="35" subjects_affected="29" subjects_at_risk="212"/>
                <counts group_id="E2" events="35" subjects_affected="32" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Medical</sub_title>
                <counts group_id="E1" events="167" subjects_affected="86" subjects_at_risk="212"/>
                <counts group_id="E2" events="193" subjects_affected="105" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Localized Infection</sub_title>
                <counts group_id="E1" events="50" subjects_affected="41" subjects_at_risk="212"/>
                <counts group_id="E2" events="63" subjects_affected="51" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The primary endpoint was not validated for use in HF trials (VAT, responder analysis, responder = 20% increase). VAT was missing or indeterminant in 30% of subjects despite use of 2 blinded core labs. ITT analysis required 10 levels of imputation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Angela Stagg, Sr. Director, Clinical and Data Operations</name_or_title>
      <organization>Impulse Dynamics (USA) Inc</organization>
      <phone>8453592389</phone>
      <email>angelas@impulse-dynamics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

